Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Projected to Reach $6.17 Billion by 2030: Increasing Prevalence Drives Growth

DUBLIN, Sept. 22, 2023 /PRNewswire/ — The “Idiopathic Pulmonary Fibrosis Treatment Market: Global Market Size, Forecast, Insights, and Competitive Landscape” report has been added to’s offering.

The global idiopathic pulmonary fibrosis (IPF) treatment market is expected to experience significant growth, with a projected Compound Annual Growth Rate (CAGR) of approximately 8.0%. By 2030, the market is set to reach $6.17 billion, up from $3.6 billion in 2023, according to a comprehensive report on the market.

Holistic Understanding of the IPF Treatment Market

This comprehensive report offers a holistic understanding of the global idiopathic pulmonary fibrosis treatment market, providing insights into market sizing, forecasts, drivers, challenges, and the competitive landscape. It presents a clear overview of the market, segmented by drug class, end-user, and region.

Company Profiles for Informed Decision-Making

The report includes detailed profiles of companies operating in the idiopathic pulmonary fibrosis treatment market. These profiles are designed to assist professionals and industry stakeholders in making informed decisions.

Companies Mentioned 

  • AdAlta Pty Ltd.
  • Angion Biomedica Corp.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • F. Hoffmann-La Roche AG (Roche Holding AG)
  • Fibrogen Inc.
  • Galapagos NV
  • Liminal BioSciences Inc.
  • Medicinova Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Vectura Group Plc.

Market Dynamics: 


  • Increasing Prevalence of Fibrotic Diseases: The growing prevalence of fibrotic diseases is a key driver of market growth.
  • Rising Geriatric Population: The aging population contributes to the increasing incidence of idiopathic pulmonary fibrosis.


  • Lack of Awareness: Limited awareness about IPF may hinder market growth.
  • Availability of Proper Treatment: The availability of effective treatments remains a challenge.

Historical and Forecast Periods

  • Base Year: 2022
  • Historical Period: 2018-2022
  • Forecast Period: 2023-2030

Market Segmentation

Drug Class

  • MAPK Inhibitors
  • Tyrosine Inhibitors
  • Autotaxin Inhibitors

End User

  • Hospitals
  • Long-term Care Facilities
  • Others

Regional Insights


  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe

North America

  • United States
  • Canada

Asia Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Rest of Asia Pacific

Latin America

  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Middle East & Africa

  • Saudi Arabia
  • Turkey
  • Iran
  • United Arab Emirates
  • Rest of Middle East & Africa

The global idiopathic pulmonary fibrosis treatment market is on a robust growth trajectory, driven by the increasing prevalence of fibrotic diseases and the rise in the geriatric population. This report equips industry professionals with essential insights for strategic decision-making.

For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


SOURCE Research and Markets

Originally published at

Part of VUGA

Part of VUGA

best company for press release distribution